This Top Small-Cap Just Became a Better Buy
When investors talk about software changing the world, few would immediately point to Semler Scientific (NASDAQ: SMLR) as an example. I think that's only because the company is flying under the radar. Among other efforts, Semler is using software to improve testing for peripheral artery disease -- or PAD -- which is underdiagnosed, inefficiently treated, and expensive to test for.
Semler recently uplisted from the OTC market to the Nasdaq, meaning that one major risk in investing in the business -- its liquidity -- was just mitigated. Here's why I think investors should look into Semler before it gets broad market attention.
Image source: Getty Images.
Source Fool.com
